Dompé is a new company record. Its research profile isn't ready yet.
dompe.comCrawled Nov 8, 2026
Dompé is committed to advancing treatments for ophthalmic, neurological and pain-related indications through NGF research, including NK, NAION and AKC.
Dompé supports scientific inquiries on product safety, efficacy, pharmacology, administration, and dosage.
Dompé Medicines: scientific profile of pharmaceutical treatments, ophthalmic R&D and Managed Access Programs providing investigational therapies.
Nerve Growth Factor at Dompé: development and industrial production of recombinant human NGF (rhNGF) Oxervate for ocular disease research and therapies.
Access the latest media materials from Dompé on biomedical research, pharmaceutical advances, and scientific updates.
The company drives innovation in science to improve patient lives and offers career opportunities.
The page lists Dompé’s career opportunities in the United States for clinical, medical, and pharmacological research experts.
Dompé fosters collaboration, continuous learning and innovation to support scientists and professionals in every stage of their growth.
The page introduces Dompé’s management team and highlights its contributions to scientific research.
Nathalie Dompé, the company's CEO, contributes to its leadership by supporting its strategic direction and scientific vision.
The page introduces Dompé’s pharmaceutical management team and provides profiles of each member.
The page describes Dompé’s pharmaceutical management team and its leaders in scientific and strategic initiatives.
Dompé: 130 years of pharmaceutical research advancing Nerve Growth Factor therapeutics, Exscalate drug discovery and precision biotech manufacturing.
Dompé Holdings Group, led by Sergio Dompé, invests in and partners with companies focused on environmental impact.
Dompé grants and donations fund medical education, clinical research and patient programs to advance science through high technological standards.
The page outlines Dompé’s history, offices, management team, ethics, and commitment to pharmaceutical quality and safety.
The company advances research on rhNGF, its biotech pipeline, and Exscalate for ophthalmic therapies and clinician technologies.
The company advances research on rhNGF, its biotech pipeline, and Exscalate for ophthalmic therapies and clinician technologies.
